Cordycepin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cordycepin
Accession Number
DB12156
Type
Small Molecule
Groups
Investigational
Description

Cordycepin has been used in trials studying the treatment of Leukemia.

Structure
Thumb
Synonyms
Not Available
External IDs
NSC-401022 / NSC-63984
Categories
UNII
GZ8VF4M2J8
CAS number
73-03-0
Weight
Average: 251.2419
Monoisotopic: 251.101839307
Chemical Formula
C10H13N5O3
InChI Key
OFEZSBMBBKLLBJ-BAJZRUMYSA-N
InChI
InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
IUPAC Name
(2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
SMILES
[H][C@@]1(CO)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C(N)N=CN=C12

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cordycepin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Cordycepin.Experimental
AgmatineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Agmatine.Experimental, Investigational
AmiodaroneThe therapeutic efficacy of Cordycepin can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cordycepin.Approved, Investigational
AmrinoneThe therapeutic efficacy of Cordycepin can be increased when used in combination with Amrinone.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Cordycepin.Approved, Investigational, Withdrawn
AranidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Aranidipine.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Cordycepin can be increased when used in combination with Azimilide.Investigational
BarnidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Barnidipine.Approved
BencyclaneThe therapeutic efficacy of Cordycepin can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of Cordycepin can be increased when used in combination with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
BioallethrinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Bioallethrin.Approved, Experimental
BuspironeThe metabolism of Buspirone can be decreased when combined with Cordycepin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Cordycepin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cordycepin.Approved
CarboxyamidotriazoleThe therapeutic efficacy of Cordycepin can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Caroverine.Experimental
CilnidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cordycepin.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Clevidipine.Approved, Investigational
CyclandelateThe therapeutic efficacy of Cordycepin can be increased when used in combination with Cyclandelate.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Cordycepin.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Cordycepin.Experimental
DarodipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Darodipine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cordycepin.Approved
DidanosineDidanosine can cause a decrease in the absorption of Cordycepin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cordycepin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Cordycepin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cordycepin.Approved
DiltiazemThe therapeutic efficacy of Cordycepin can be increased when used in combination with Diltiazem.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Cordycepin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Cordycepin.Approved, Investigational
DotarizineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Dotarizine.Investigational
EfonidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Efonidipine.Approved, Investigational
EperisoneThe therapeutic efficacy of Cordycepin can be increased when used in combination with Eperisone.Approved, Investigational
EthosuximideThe therapeutic efficacy of Cordycepin can be increased when used in combination with Ethosuximide.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Cordycepin.Approved
FelodipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Fendiline.Withdrawn
Fish oilThe therapeutic efficacy of Cordycepin can be increased when used in combination with Fish oil.Approved, Nutraceutical
FlunarizineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Flunarizine.Approved
FluspirileneThe therapeutic efficacy of Cordycepin can be increased when used in combination with Fluspirilene.Approved, Investigational
FosphenytoinThe serum concentration of Cordycepin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabapentinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of Cordycepin can be increased when used in combination with Gallopamil.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Cordycepin.Experimental
IsradipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Isradipine.Approved, Investigational
LacidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Lamotrigine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Cordycepin.Experimental
LercanidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Cordycepin can be increased when used in combination with Levetiracetam.Approved, Investigational
LidoflazineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Lidoflazine.Experimental
LoperamideThe therapeutic efficacy of Cordycepin can be increased when used in combination with Loperamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Cordycepin.Approved
Magnesium sulfateThe therapeutic efficacy of Cordycepin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Manidipine.Approved, Investigational
MentholThe therapeutic efficacy of Cordycepin can be increased when used in combination with Menthol.Approved
MethsuximideThe therapeutic efficacy of Cordycepin can be increased when used in combination with Methsuximide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Cordycepin.Experimental
MibefradilThe therapeutic efficacy of Cordycepin can be increased when used in combination with Mibefradil.Investigational, Withdrawn
NaftopidilThe therapeutic efficacy of Cordycepin can be increased when used in combination with Naftopidil.Investigational
NicardipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nicardipine.Approved, Investigational
NifedipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nitrendipine.Approved, Investigational
NylidrinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Nylidrin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Cordycepin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Cordycepin can be increased when used in combination with Otilonium.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Cordycepin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cordycepin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Cordycepin.Experimental
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cordycepin.Approved, Vet Approved
PinaveriumThe therapeutic efficacy of Cordycepin can be increased when used in combination with Pinaverium.Approved
PrenylamineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with Cordycepin.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Cordycepin.Experimental
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cordycepin.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cordycepin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Cordycepin.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cordycepin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Cordycepin.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cordycepin.Approved, Investigational
SeletracetamThe therapeutic efficacy of Cordycepin can be increased when used in combination with Seletracetam.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Cordycepin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Cordycepin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Cordycepin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cordycepin.Approved, Investigational
TerodilineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Cordycepin can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TranilastThe therapeutic efficacy of Cordycepin can be increased when used in combination with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
TrimebutineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Cordycepin can be increased when used in combination with Trimethadione.Approved
VerapamilThe therapeutic efficacy of Cordycepin can be increased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of Cordycepin can be increased when used in combination with Vinpocetine.Investigational
WIN 55212-2The therapeutic efficacy of Cordycepin can be increased when used in combination with WIN 55212-2.Experimental
ZiconotideThe therapeutic efficacy of Cordycepin can be increased when used in combination with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Cordycepin.Approved
ZonisamideThe therapeutic efficacy of Cordycepin can be increased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C08431
PubChem Compound
6303
PubChem Substance
347828450
ChemSpider
6064
BindingDB
50144950
ChEBI
29014
ChEMBL
CHEMBL305686
HET
3AD
Wikipedia
Cordycepin
PDB Entries
1fa0 / 3b4b / 3b4c / 3onf / 5m5k

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP-0.85ALOGPS
logP-1.4ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)4.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area119.31 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity62.1 m3·mol-1ChemAxon
Polarizability24.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Purine 3'-deoxyribonucleosides
Direct Parent
Purine 3'-deoxyribonucleosides
Alternative Parents
6-aminopurines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds / Primary amines
show 3 more
Substituents
Purine 3'-deoxyribonucleoside / 6-aminopurine / Imidazopyrimidine / Purine / Aminopyrimidine / N-substituted imidazole / Pyrimidine / Imidolactam / Azole / Imidazole
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
adenosines, 3'-deoxyribonucleoside (CHEBI:29014)

Drug created on October 20, 2016 15:29 / Updated on July 02, 2018 19:33